Business Wire

DeepGreenX Group and Hues Capital Launch $10 Billion USD Fund to Accelerate AI, Green Energy, and Computing Power

9.12.2024 14:00:00 EET | Business Wire | Press release

Share

DeepGreenX Group Inc. (“DeepGreenX,” “DXG,” or the “Company”), an AI-enabled green energy and technology company, and Hues Capital (“Hues”), a leading capital provider enabling financial technology ecosystems, AI, and green energy enterprises, jointly announced the formation of a new $10 billion USD fund (the “Fund”) to drive global advancements in AI, green energy, and computing power and accelerate sustainability initiatives worldwide.

DeepGreenX and Hues will each hold a 50% stake and act as co-general partners in the $10 billion USD DXG-Hues parent fund, which will be based in the EU and comprise two $5 billion USD sub-funds: the DXG-Hues AI Computing Infrastructure Fund and the DXG-Hues AI Energy Fund. The former will focus on global investments in AI computing power and green energy infrastructure projects, while the latter will target emerging enterprises in the fields of AI ecosystems, fintech, and green energy.

This initiative will bring together seasoned professionals with deep expertise in technology and finance. The Fund’s leadership team will include Miao Wei, former Vice President of Alibaba Cloud, and Dr. Chen Jidong, former Vice President of Ant Group's Digital Technology Division and Chief Product Officer of Security Technology. In connection with the formation of the Fund, Hues founder, Chairman, and Chief Executive Officer Dr. Jim Lai will join the Board of Directors of DeepGreenX.

Dr. Lai was previously Vice President of Tencent, where he led the Financial Internet Technology (FiT) division and contributed to the creation of WeChat Pay, WeChat Red Envelope, and the management of Tencent’s trillion-yuan Wealth Management Platform. He also played a critical role in Tencent's investment strategy, investing into dozens of WeChat Pay ecosystem companies founded by visionary entrepreneurs. He collaborated on incubating and scaling numerous industry-leading unicorns, many of which have gone public, including those focused on AI-driven big data and financial technology, as well as world-leading financial institutions. In his role as a director for several post-investment companies on behalf of Tencent, Dr. Lai has been instrumental in fostering collaboration and synergy within Tencent’s WeChat Pay ecosystem. These companies have also consistently achieved unicorn status, gone public, and generated significant returns for their investors.

“We are thrilled to launch this new Fund with Hues, which is a product of our shared vision that new, innovative capital sources are required for these new, innovative ecosystems. With this collaboration, we are taking a bold and strategic step forward in harnessing AI-driven computing power, advancing sustainable energy solutions, and catalyzing innovative financial systems,” said Barclay Knapp, CEO of DeepGreenX. “We believe this Fund will provide substantial financial resources to high-impact enterprises and projects, accelerating the transition to a global green economy while promoting long-term sustainability.”

DeepGreenX is a rapidly developing international platform company connecting green energy, nature-based and real-world assets (RWA), sustainable computing power, and AI developer communities to new-era digital trading and banking systems. The Company deploys an AI platform-as-a-service (AI PaaS) model to extract and convert sustainability, RWA, and other data into verified digital financial instruments such as renewable energy certificates (REC), tokens, and its own-branded DXG Certificates, which the Company then transacts and monetizes on digital trading and banking systems on behalf of its enterprise clients. Alongside its platform, DeepGreenX is facilitating the synergistic development of human intelligence plus AI applications via a 190,000-person strong AI developer community.

“Hues’ depth of expertise will be instrumental in supporting DeepGreenX’s efforts to establish and operate a global CBDC clearing network,” said Dr. Lai. “This collaboration will also strengthen strategic integration across both companies’ ecosystems, spanning portfolios in AI, green energy, and computing power.”

Hues boasts a foundation of global institutional LPs, with a mission to enable large-scale financial technology ecosystems, AI technology, and green energy enterprises to scale internationally. It seeks to build a globally integrated ecosystem that bridges AI, financial technology, and sustainable energy solutions. It is led by Dr. Lai, former founding Chairman of Fusion Bank, with stakeholders such as Tencent, the Hong Kong Stock Exchange, and ICBC (Asia).

About DeepGreenX

Founded in 2020 and headquartered in Seoul, DeepGreenX Group Inc. is a digital transformation company providing AI and financialization solutions for sustainability initiatives and real-world assets worldwide. With developing operations in 20 cities across four continents, DeepGreenX employs proprietary AI technology and a PaaS model to capture and verify attractive data assets, digitally convert those assets into digital financial products, and then transact with them on global digital trading and banking platforms on behalf of its enterprise customers. For more information on DeepGreenX, visit: www.DeepGreenX.com.

About Hues Capital

Founded in 2023, Hues Capital is a PE fund management company with an internet background, aimed at helping entrepreneurs develop their own companies and businesses in the internet ecosystems of China, Japan, and Southeast Asia. The founder and team of Hues Capital have created the largest mobile payment ecosystem covering the world, incubating and empowering numerous successful unicorn enterprises in the FinTech industry. The current investment areas of Hues Capital mainly include three directions: FinTech, AI, Supercomputing Data Center and New energy EV.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241208029753/en/

Contacts

DeepGreenX:
Prosek Partners
Kiki Tarkhan / Forrest Gitlin
DeepGreenX@prosek.com

Hues Capital:
Rongping Hu
enquiry@hues.capital
+86 755 2267 0610

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye